Share:
The European Association for the Study of the Liver (EASL) Congress was held in Vienna, Austria on 21-24 June 2023. Check out the official website of the Congress.
- Aligos Therapeutics presents data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023
- Arbutus presents preliminary AB-729 and pegylated interferon alfa-2a combination data at the EASL Congress 2023
- Assembly Biosciences presents new data highlighting entry inhibitor and core inhibitor programs at EASL’s International Liver Congress™ 2023
- Virion Therapeutics presents VRON-0200 preclinical data showing direct correlations between intrahepatic CD8+ T cells and hepatitis B virus declines (HBV) at EASL 2023
- Vaccitech to present positive final data at EASL Congress for Phase 1b/2 HBV002 study in adults with chronic hepatitis B
- Precision BioSciences announces oral presentation of positive ARCUS® gene editing data at International Liver Congress 2023
- Brii Bio announces new data from partners underscoring potential for HBV functional cure at EASL™ Congress 2023
- Vir Biotechnology presents new data evaluating the potential for VIR-2218 and VIR-3434 as therapies for chronic hepatitis B and hepatitis D
- Healio: Older age, high HBsAg levels linked to increased risk for flare after treatment withdrawal
- Gilead Sciences: Hepcludex® (bulevirtide) demonstrates sustained efficacy and safety profile in people with chronic hepatitis delta virus at 96 weeks
— SEE ALSO:
- MedPage Today: Antiviral offers ‘glimmer of hope’ in chronic hepatitis D
- Medical Xpress: Exploring the use of bulevirtide as a new weapon against hepatitis D
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.